Abstral EU success continues. Orexo receives sales milestone of 3.3 MEUR.

Uppsala, Sweden – May 25, 2012 - Orexo AB (STO: ORX) announced today that accumulated sales of Abstral has surpassed 65 MEUR, which was faster than earlier anticipated and results in a 3.3 MEUR milestone payment from ProStrakan.

Abstral is the leading new fast acting fentanyl product in Europe and this position has been further strengthened during the first four months of 2012. Abstral has continued to win market share. The growth during first quarter of 2012 was 39%, driven especially by the key markets France, Italy and Spain.

Anders Lundström, Chief Executive Officer, of Orexo said:
“I am pleased to see continued strong Abstral sales growth in Europe. The product has during 2012 further strengthened its leading market position among the new fast acting fentanyl products for treatment of break through pain in cancer patients. Abstral continued success in Europe highlights the advantages of Orexo’s proprietary sublingual formulation technology.”

For further information, please contact:
Carl-Johan Blomberg, Chief Financial Officer
Phone: +46 (0)706 33 67 11, E-mail:
carl-johan.blomberg@orexo.com

Nikolaj Sørensen, Chief Commercial Officer
Phone: +46 (0)703 50 78 88, E-mail:
nikolaj.sorensen@orexo.com

About Orexo
Orexo AB is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations.

Orexo has a portfolio of revenue generating EU and US approved products currently marketed under licence and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharma companies.

Orexo AB is Swedish headquartered with 100 employees and listed on NASDAQ-OMX. The largest shareholders are Danish Novo A/S and Swedish HealthCap. More information can be found at www.orexo.com

About Abstral
Abstral is the novel, rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl, a well-established opioid used for the management of episodes of breakthrough pain experienced by cancer patients who are already receiving opioid analgesics for chronic pain.

Note: This is information that Orexo AB (publ) discloses pursuant to the Financial Instruments Trading Act and/or Securities Market Act. The information was provided for public release on May 25, 2012 at 10:00 CEST. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.

Tags:

About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.